Amneal EVP & Chief Commercial Officer–Specialty Joseph Todisco to depart by May 15, 2022

Amneal Pharmaceuticals, Inc.

Joseph Todisco is stepping down from his role as EVP, Chief Commercial Officer – Specialty.
He will remain through a transition period expected to end May 15, 2022.
Todisco is leaving to pursue an opportunity outside the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Todisco

Executive Vice President, Chief Commercial Officer – Specialty

AMRX · Amneal Pharmaceuticals, Inc.

Effective: 2022-05-15
Filed: March 16, 2022, 7:59 PM ET

On March 15, 2022, Joseph Todisco, Executive Vice President, Chief Commercial Officer – Specialty for Amneal Pharmaceuticals, Inc. (the “Company”), informed the Company of his decision to step down from his role to pursue another opportunity outside of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Todisco departed as Executive Vice President, Chief Commercial Officer – Specialty at Amneal Pharmaceuticals, Inc..

Action: stepped down
Role: Executive Vice President, Chief Commercial Officer – Specialty

Exact text from the filing

On March 15, 2022, Joseph Todisco, Executive Vice President, Chief Commercial Officer – Specialty for Amneal Pharmaceuticals, Inc. (the “Company”), informed the Company of his decision to step down from his role to pursue another opportunity outside of the Company.

View on SEC.gov

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-077358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.